Clinical Trial Search

Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale

Primary: Number of Patients With SALT50 — 1; 1 Participants

Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants

Primary: Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -25.6; -30.4; -25.9; -6.3 percent — p=0.011

Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…

Primary: Total Number of Participants With At Least 50% Hair Regrowth — 1 Participants

Primary: Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 — 30.65; 22.31; 23.39; 14.29 Percentage of…

Primary: Change in Severity of Alopecia Areata Tool (SALT) Score — -3.8; -3.4 units on a scale — p=0.97

Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 10 percent change

Primary: Change in Gene Expression Th2/IL-13, "T22"/IL-22, S100A7 and S100A8, Th1/IFN-gamma, and Th17/IL-17A Jointly Correlated — -0.28 z-score

Primary: Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 — 2.6; 17.3; 32.5 percentage of participants — p=<0.001

Primary: Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24 — 9.3; 21.4; 47.4; 58.3…

Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 30.7 Percent change — p=<0.0001

Primary: Change in SALT Score — 65.8; 24.8; 7.3 score on a scale

Primary: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24 — 0.8; 29.6; 41.5 percentage of participants — p=<0.0001

Primary: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24 — 0.8; 33.0; 38.3 Percentage of participants — p=<0.0001

Primary: Mean Change in Severity of Alopecia Tool (SALT) Score — 22.8 percent change in SALT score

Primary: Percent Change From Baseline in SALT Score at Week 24 — -12.6 percent change in score on a scale

Primary: Total Number of Responders — 8 Participants

Primary: Clinician's Eyebrow Assessment — 0 score on a scale

Primary: Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3 — 5.3; 21.7; 35.2 percentage of participants — p=<0.001

Primary: Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period — -13.79; -21.43; 0.35 Percent change of scalp surface area — p=0.2579

Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 3 Participants

Primary: Mean Change in Physician Global Assessment of Improvement (PGA-I) — 0.07 score on a scale

Primary: Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 32.54; 50.59; 1.41 units on a scale — p=<.0001

Primary: Change in Alopecia Areata Half Head Severity Score (AAHHSS) at 12 Weeks Compared to Baseline — -17.75 score on a scale

Primary: Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose…

Primary: Number of Participants With Adverse Events as a Measure of Safety — 308; 224 Participants

Primary: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 46.4; 18.0 percent change

Primary: Area Under the Plasma Concentration-Time Profile Over the Dosing Interval of 24 Hours, at Steady State (AUC24ss/AUCtau) of Ritlecitinib on Day 7 — 437.5 Nanogram*hours…